RCM
HQL

Raleigh Capital Management’s abrdn Life Sciences Investors HQL Stock Holding History

Raleigh Capital Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-104
Closed -$1.47K – 1026
2024
Q2 		$1.47K Buy
+104
New +$1.41K ﹤0.01% 815

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
AIA
Absolute Investment Advisers Rosemary Beach, Florida $852M AUM 0.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Raleigh Capital Management's HQL Position: Q3 2024 in Review

Raleigh Capital Management sold out of abrdn Life Sciences Investors (HQL) in Q3 2024, closing a stake of 104 shares — an estimated $1.47K sold.

Raleigh Capital Management first reported a position in HQL in Q2 2024 and held it in 1 quarter. The position peaked at $1.47K in Q2 2024. 74 funds tracked by Wall St. Rank hold HQL as of Q3 2024.

  • Raleigh Capital Management reported no remaining abrdn Life Sciences Investors position as of Q3 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 104 abrdn Life Sciences Investors shares in Q3 2024, an estimated $1.47K.
  • Raleigh Capital Management first reported a position in abrdn Life Sciences Investors in Q2 2024 and held it in 1 quarter.
  • Raleigh Capital Management's abrdn Life Sciences Investors position peaked at $1.47K in Q2 2024.
  • 74 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2024.

Based on Raleigh Capital Management's 13F filing for Q3 2024, filed 21 Oct 2024.